News & Updates

Show Multimedia Only

Inactivated vaccine receipt during natalizumab treatment safe, immunogenic in MS patients

17 Apr 2024

For patients with multiple sclerosis (MS) who are receiving treatment with natalizumab, getting shots with inactivated vaccines is safe and immunogenic, with the positive results persisting regardless of the duration of natalizumab therapy, as shown in a study.

Inactivated vaccine receipt during natalizumab treatment safe, immunogenic in MS patients

17 Apr 2024

Amivantamab plus chemo tied to better outcomes in NSCLC

17 Apr 2024 by

Treatment with amivantamab (ami) in combination with chemotherapy (chemo) results in substantially longer time to treatment discontinuation (TTD), time to subsequent therapy (TTST), and progression-free survival (PFS) after first subsequent therapy (PFS2) in patients with EGFR-mutant advanced nonsmall cell lung cancer (NSCLC) following progression on osimertinib, as shown in a postprogression analysis.

Amivantamab plus chemo tied to better outcomes in NSCLC

17 Apr 2024

Panobinostat plus vincristine/irinotecan shows potential in hepatoblastoma

17 Apr 2024

Use of panobinostat in combination with vincristine and irinotecan chemotherapy provides effective tumour response in models developed from patients with high-risk, relapsed, and treatment-refractory hepatoblastoma (HB), according to a study.

Panobinostat plus vincristine/irinotecan shows potential in hepatoblastoma

17 Apr 2024

GLP-1RAs may improve long-term liver outcomes in T2D patients with MASLD

17 Apr 2024

For patients with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD) cirrhosis, treatment with glucagon-like peptide-1 receptor agonists helps reduce the risk of hepatic decompensation, portal hypertension, hepatocellular carcinoma, and liver transplantation, according to a study.

GLP-1RAs may improve long-term liver outcomes in T2D patients with MASLD

17 Apr 2024

MMF trumps azathioprine for remission in treatment-naive AIH

16 Apr 2024 by

Treatment with mycophenolate mofetil (MMF) in combination with prednisolone results in better biochemical remission rates at 24 weeks than the use of azathioprine plus prednisolone in patients with treatment-naïve autoimmune hepatitis (AIH), reports a study.

MMF trumps azathioprine for remission in treatment-naive AIH

16 Apr 2024

COVID rebound common, does not differ after VV116 vs nirmatrelvir–ritonavir treatment

15 Apr 2024 by

Many patients with mild-to-moderate COVID-19 experience a resurgence of the virus as well as symptoms after a standard 5-day course of treatment with either VV116 or nirmatrelvir–ritonavir, as shown in a study from China.

COVID rebound common, does not differ after VV116 vs nirmatrelvir–ritonavir treatment

15 Apr 2024

$Long-term TDF use ups fracture risk in older CHB patients$

Long-term TDF use ups fracture risk in older CHB patients

15 Apr 2024

Use of tenofovir disoproxil fumarate (TDF) for ≥24 months increases the risk of fracture in older patients with chronic hepatitis B (CHB), reports a study.

Long-term TDF use ups fracture risk in older CHB patients

15 Apr 2024

Intravesical interferon a promising treatment option for interstitial cystitis

14 Apr 2024

Intravesical interferon instillation appears to benefit women with interstitial cystitis (IC), with a recent study showing that the approach helps improve patient-reported and objective outcomes compared with hyaluronic acid without serious adverse events.

Intravesical interferon a promising treatment option for interstitial cystitis

14 Apr 2024

Concomitant use of antidepressants, oral anticoagulants raises bleeding risk in AF patients

14 Apr 2024 by

Patients with atrial fibrillation (AF) who take oral anticoagulants (OACs) and selective serotonin reuptake inhibitors (SSRIs) at the same time appear to have a higher likelihood of major bleeding.

Concomitant use of antidepressants, oral anticoagulants raises bleeding risk in AF patients

14 Apr 2024

SGLT2 inhibitors suitable for patients with T2D and NAFLD

14 Apr 2024

Clinicians may favour prescribing sodium-glucose cotransporter 2 (SGLT2) inhibitors to patients with both type 2 diabetes (T2D) and nonalcoholic fatty liver disease (NAFLD), with the drugs having potential benefits in terms of NAFLD regression and reduced incidences of adverse liver-related outcomes, according to a study.

SGLT2 inhibitors suitable for patients with T2D and NAFLD

14 Apr 2024

News & Updates

Filter by Specialty:

Specialty:

Inactivated vaccine receipt during natalizumab treatment safe, immunogenic in MS patients

Inactivated vaccine receipt during natalizumab treatment safe, immunogenic in MS patients

Amivantamab plus chemo tied to better outcomes in NSCLC

Amivantamab plus chemo tied to better outcomes in NSCLC

Panobinostat plus vincristine/irinotecan shows potential in hepatoblastoma

Panobinostat plus vincristine/irinotecan shows potential in hepatoblastoma

GLP-1RAs may improve long-term liver outcomes in T2D patients with MASLD

GLP-1RAs may improve long-term liver outcomes in T2D patients with MASLD

MMF trumps azathioprine for remission in treatment-naive AIH

MMF trumps azathioprine for remission in treatment-naive AIH

COVID rebound common, does not differ after VV116 vs nirmatrelvir–ritonavir treatment

COVID rebound common, does not differ after VV116 vs nirmatrelvir–ritonavir treatment

Long-term TDF use ups fracture risk in older CHB patients

Long-term TDF use ups fracture risk in older CHB patients

Intravesical interferon a promising treatment option for interstitial cystitis

Intravesical interferon a promising treatment option for interstitial cystitis

Concomitant use of antidepressants, oral anticoagulants raises bleeding risk in AF patients

Concomitant use of antidepressants, oral anticoagulants raises bleeding risk in AF patients

SGLT2 inhibitors suitable for patients with T2D and NAFLD

SGLT2 inhibitors suitable for patients with T2D and NAFLD